Advancing an Innovative Collection of Autoimmune Therapy Candidates
We are developing a portfolio of engineered T cell therapy candidates to treat autoimmune diseases. Our lead Chimeric Antigen Receptor T cell for Autoimmunity (CARTA) candidate, CABA-201, is being developed for systemic lupus erythematosus as well as other severe autoimmune diseases.
Our lead Chimeric AutoAntibody Receptor T (CAART) cell therapy product candidate, DSG3-CAART, is being evaluated in the DesCAARTes™ trial, targeting B cells that cause mucosal pemphigus vulgaris (mPV), a life-threatening autoimmune blistering disease affecting the mucous membranes. The MusCAARTes™ trial of MuSK-CAART in MuSK-associated myasthenia gravis is ongoing, with the development strategy accelerated through learnings informed by the DSG3-CAART experience. We also have several preclinical and discovery-stage targeted cell therapy candidates under development, all created with the vision of improving the lives of patients with autoimmune diseases.